Small Cell Lung Cancer

New first-line ES-SCLC data show iza-bren plus serplulimab drives 88% responses and manageable safety, setting up phase 3 trials.

Mohamed K. Mohamed, MD, PhD, discusses how CIM disrupts treatment, burdens patients, and why a proactive management approach is critical in SCLC care.

ELCC 2026 spotlights lung cancer breakthroughs—ADCs, EGFR combo sequencing, HER2 TKIs and SCLC bispecifics—reshaping treatment choices.

IASLC TTLC 2026 spotlights patient voices, ctDNA MRD, EGFR co-mutations, and ADCs—plus real-world gaps in testing and multidisciplinary lung care.

Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.

IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.

Explore frontline chemo‑immunotherapy choices in extensive-stage SCLC, NCCN updates, and why patient drop-off shapes second- and third-line care.

Durvalumab boosts survival in limited-stage SCLC, yet US costs miss value thresholds, fueling urgent debates on access and pricing.

Rebecca Siegel, MPH, reveals key insights on lung cancer trends, survival rates, and the need for targeted interventions in diverse populations.

During a live event, Joshua K. Sabari, MD, discussed subgroup analyses and safety outcomes of the IMforte trial in extensive-stage small cell lung cancer.

Promising interim results highlight the potential of Olvi-Vec in treating advanced lung cancer, showcasing efficacy and safety in challenging patient populations.

Martin F. Dietrich, MD, PhD, discusses the use of the CDK4/6 inhibitor trilaciclib to address myelosuppression associated with chemotherapy in small cell lung cancer.

During a live event, Joshua K. Sabari, MD, discussed outcomes of the phase 3 IMforte trial in extensive-stage small cell lung cancer.

The FDA has granted a full approval to tarlatamab-dlle for extensive-stage small cell lung cancer.

Small cell lung cancer treatment evolves with groundbreaking therapies, improving survival rates and offering new hope for patients in 2024 and beyond.

A groundbreaking clinical trial begins for 225Ac-SSO110, targeting aggressive cancers like extensive-stage small cell lung cancer and Merkel cell carcinoma.

During a live event, Wade T. Iams, MD, MSCI, discussed potential ways to determine which patients benefit most from additional therapy for extensive-stage small cell lung cancer.

Zocilurtatug pelitecan shows promising results as a DLL3-targeted therapy for small cell lung cancer, with high response rates and ongoing trials.

During a live event, Wade T. Iams, MD, MSCI, examined outcomes of the phase 3 IMforte trial in extensive-stage small cell lung cancer.

New findings reveal I-DXd's promising efficacy in treating extensive-stage small cell lung cancer with brain metastases, showcasing significant response rates.

Tarlatamab-dlle shows significant overall survival benefits over chemotherapy in small cell lung cancer, even in platinum-resistant cases.

Tarlatamab combined with frontline chemoimmunotherapy shows promising safety and efficacy in extensive-stage small cell lung cancer patients.

T-cell engagers are a welcome addition to the oncologist's armamentarium, but managing associated adverse events is important to obtain the drugs' optimal benefit. Here are some suggestions.

Tarlatamab-dlle combined with anti-PD-L1 therapy shows remarkable survival rates and manageable safety in extensive-stage small cell lung cancer patients.